(49 days)
None
Not Found
No
The summary describes a system for collecting, storing, and purifying RNA from blood using chemical and physical processes. There is no mention of algorithms, data analysis, or learning processes that would indicate the use of AI/ML.
No.
The device is intended for the collection, storage, and transport of blood for subsequent isolation and purification of host RNA for RT-PCR used in molecular diagnostic testing. It is a diagnostic tool, not a therapeutic one.
No
While the extracted RNA is intended for "molecular diagnostic testing," this device itself is a collection and purification system, not a device that performs the diagnostic test or provides a diagnostic result. It prepares the sample for subsequent diagnostic testing.
No
The device description clearly states it consists of physical components: blood collection tubes and a nucleic acid purification kit, which include various chemical solutions, tubes, columns, etc. It is a system for collecting, storing, and purifying RNA, not a software application.
Based on the provided information, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states that the system is for "subsequent isolation and purification of host RNA from whole blood for RT-PCR used in molecular diagnostic testing." This directly aligns with the definition of an in vitro diagnostic device, which is used to examine specimens from the human body to provide information for diagnostic purposes.
- Device Description: The device is a blood collection tube and a purification kit designed to process a biological specimen (whole blood) for analysis.
- Performance Studies: The document details various analytical performance studies (Precision/Reproducibility, RNA Purity, DNA Contamination, RNA Yield, RT-PCR Inhibition, Linearity, Stability) which are typical evaluations for IVD devices to demonstrate their reliability and suitability for diagnostic use.
- Intended User: The device is for "professional use only," which is common for IVD devices used in clinical or laboratory settings.
The fact that it is used to prepare a sample (RNA from blood) for a downstream diagnostic test (RT-PCR) makes it an integral part of the in vitro diagnostic process.
N/A
Intended Use / Indications for Use
The PAXgene™ Blood RNA System consists of a blood collection tube (PAXgene™ Blood RNA Tube) and nucleic acid purification kit (PAXgene™ Blood RNA Kit). It is intended for the collection, storage, and transport of blood and stabilization of intracellular RNA in a closed tube and subsequent isolation and purification of host RNA from whole blood for RT-PCR used in molecular diagnostic testing.
Performance characteristics for the PAXgene™ Blood RNA System have only been established with "cfos and IL1B." The user is responsible for establishing appropriate PAXgene™ Blood RNA System performance characteristics for other target transcripts.
Product codes (comma separated list FDA assigned to the subject device)
NTW
Device Description
The PAXgene™ Blood RNA System consists of:
- the PAXgene™ Blood RNA tubes and .
- the PAXgene™ Blood RNA kit. .
The PAXgene™ Blood RNA tube is of a sterile, plastic, evacuated blood collection tube containing stabilization solution (tetradecyl trimethyl-ammonium oxalate and tartaric acid. These components serve to lyse cells, protect RNA molecules from degradation by ribonucleases (RNases) and prevent induction of gene expression.
The kit consists of 5 aqueous buffer solutions for resuspending, binding, washing, and eluting RNA, RNase-free water, proteinase K, an RNase-Free DNase set, spin columns, microcentrifuge tubes, processing tubes, and secondary blood collection tube closures.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
For professional use only
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
CFOS/18S rRNA and IL1B/18S rRNA Q-RT-PCR Duplex assays. Objective: The sponsor submitted validation and performance data for two uncleared O-RT-PCR assays for the assessment of performance of the PAXgene Blood RNA System in comparison to a K2EDTA blood collection tube and acid phenol RNA extraction. The assays determine quantitativly the relative level of the c-fos and IL-1ß transcripts compared to 18S rRNA in RNA samples derived from human whole blood. Since CFOS and IL1B offer no diagnostic information, these assays are not intended for diagnostic use. They are ONLY intended for demonstrating that the PAXgene Blood RNA System can be used for RT-PCR.
The validation study uses two types of samples:
K2EDTA (TOTAL: 250 ml blood):
- 5 donors with 5 tubes per donor ●
- 10 ml blood per EDTA tube ●
- RNA was isolated via OIAzol and RNeasy columns, pooled and concentrated via MinElute spin column
- Purified, concentrated RNA was analyzed for yield and purity, aliquoted, and stored at -20 °C.
PAXgene (TOTAL: 960 ml blood):
- 48 donors, 8 tubes per donor (total of 384 PAXgene tubes) ●
- 2.5 ml blood per PAXgene tube
- tubes were incubated at RT for 2 hrs
- RNA was purified, DNase treated, concentrated via MinElute spin ● column and pooled.
- Purified, concentrated RNA was analyzed for yield and purity, aliquoted, and stored at -20 °C.
Experimental design of validation experiments:
The sponsor addressed repeatability and reproducibility and defines these terms within the document as follows:
The repeatability of the assay (within-run precision or intra-assay variability), is the variability of the results from repeated measurements:
- using the same two source samples (n = 10 for each sample) .
- . in the same laboratory (same equipment and same experimenter),
- on the same day, ●
- with the same reagents (identical lots) and ●
- . in the same run.
The repeatability of individual runs is expressed as the weighted mean repeatability used for the calculation of overall precision. The weighted mean repeatability is determined and is included in the overall precision calculation.
The reproducibility of the assay, (robustness, run-to-run precision, or inter-assay variability), is the variability of results from repeat measurements
- using the same two source samples .
- in different laboratories (different lots, different equipment and . different experimenters)
- . on different days
- . and in different runs.
Therefore, reproducibility investigations involve repeats of the complete experiment in different laboratories. To establish the suitability of the precision for day-to-day work, different lots of reagents are investigated as additional parameters that may have a negative impact on precision. The reproducibility between laboratories is determined, but also not specified in detail, because it is included in the overall precision calculation and therefore will be assessed as its part.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
-
Analytical performance:
a. Precision/Reproducibility:
Objective: The sponsor submitted validation and performance data for two uncleared O-RT-PCR assays for the assessment of performance of the PAXgene Blood RNA System in comparison to a K2EDTA blood collection tube and acid phenol RNA extraction. The validation study uses two types of samples: K2EDTA (TOTAL: 250 ml blood from 5 donors) and PAXgene (TOTAL: 960 ml blood from 48 donors). The sponsor addressed repeatability and reproducibility using various experimental designs, including different reagent combinations, runs, and RNA samples (K = calibrator RNA, T = test RNA). For Precision/Reproducibility of the PAXgene Blood RNA System, two experiments were performed. Experiment 1: 14 donors, 12 tubes per donor (total 168 PAXgene tubes), one lot of PAXgene Blood RNA system, 3 technicians. RNA yield and purity were determined. Experiment 2: 30 donors, 12 tubes per donor (total 360 PAXgene tubes), blood from 3 donors pooled into 10 donor pools with 36 tubes each. PAXgene Blood RNA system Lot No. VL1, VL2, VL3, 3 technicians. RNA yield, purity, and electropherograms were determined. The isolated total RNA was further tested for degradation with the CFOS and IL1B Q-RT-PCR assay.
Results: The sponsor performed an appropriate validation of their submitted assay by using 3 different component lots, in the hands of 3 different experimenters, in 3 different laboratories (equipment), on 3 different days. The sponsor provided all raw CT data and demonstrated the performance of their assays within the expected limits. The sponsor was able to show that the RNA yield and the RNA purity and quality were within the specification ranges. The min/max % CV repeatability for the quadruplicate preparation per donor pool within each lot and user were 3.4 and 28.8, respectively, with an overall % CV of 11.9. The min/max % CVs reproducibility within each user and between all lots were 8.7 and 20.1, respectively, with an overall % CV of 14.9. The min/max % CV reproducibility within all lots and between all users were 8.7 and 23.1, respectively, with an overall % CV of 16.4. The electropherograms demonstrated that the device repeatedly generates high quality total cellular RNA from whole blood. The Q-RT-PCR assay demonstrated that the transcripts CFOS and IL1B can be repeatedly measured within the assays limits utilizing different device lots, at different days, with different users in different laboratories.RNA Purity, DNA Contamination, RNA Yield.
Objective: Determination of the purity of RNA in samples, the genomic DNA (gDNA) in RNA samples and the nucleic acid yield from human whole blood specimens taken from normal subject population resulting from collection and processing of human whole blood in the PAXgene RNA Blood System.
Experimental design: 10 donors, 2 tubes per donor (total 20 PAXgene tubes) + 1 EDTA tube per donor for WBC count (10 EDTA tubes). Storage for 24 hrs at 18-22 ℃, tubes were processed, RNA isolated. RNA yield and purity were determined via absorbance measurement at 260 and 280 nm. Percent gDNA in total nucleic acid preparation was determined using beta-actin PCR.
Results: All samples for all parameter fulfilled the acceptance criteria.RT-PCR Inhibition.
Objective: Determination of RT-PCR inhibition introduced into RNA isolates by components of the PAXgene Blood RNA Kit.
Experimental Design: 22 blank eluates form columns. Template RNA for RT-PCR assay was isolated from confluent layer of HeLa cells. Test samples were formulated each containing 40 ng of HeLa RNA template plus 0, 10, 20, 30, 40% volume of volume of blank eluate. Template RNA with eluate was tested in duplicate in a one-step ACTB RT-PCR assay.
Results: All samples demonstrated that the kit components do not introduce any inhibition for an RT-PCR assay.b. Linearity/assay reportable range:
The linearity and range was determined within 0.2 to 7.8 ng for CFOS and 0.1 to 7.8 ng for IL1B total input nucleic acid per reaction. The total input mass of nucleic acid per reaction can contain up to 25% DNA for CFOS and up to 5% DNA for IL1B without affecting the performance characteristics of the assay.Traceability, Stability, Expected values (controls, calibrators, or methods): C. Stability of PAXgene Tubes:
Objective: Determine the shelf life of the PAXgene Blood RNA Tube. Determination of physical attributes (draw volume, liquid additive volume, closure performance) and chemical attributes (pH, conductivity, density, chemical component concentration) of the tubes. Analysis of tube function: RNA yield, Purity, Relative levels of CFOS and IL1B. Blood was collected in PAXgene tubes that had been stored at designated test time points (TTP's).
Results: Accelerated stability studies have been completed. Real time stability studies are ongoing, and only results of 6 months storage at 25°C are presented. The sponsor interprets that the data support a shelf live of 19 months storage at 25 °C. The physical attributes, chemical attributes, and functional performance were in the expected ranges for the 6 months real time storage.Stability of PAXgene Blood RNA Kit component:
Objective: Determine the shelf life of the PAXgene Blood RNA Kit component. Evaluation of different storage conditions via: Real time and accelerated stability study, Open bottle study, Simulated transportation study (-20°C-40°C). Determination of functional stability done with purified HeLa cell RNA as starting material. Evaluation of physical and chemical parameters: pH, conductivity, density. Bioburden Analysis.
Results: The RNA recovery, CV of recovery, degree on inhibition, pH, conductivity, and density (for all buffers) were in the expected ranges for the 6 months real time storage. Furthermore, the Proteinase K and the DNase I activity performed to the sponsors claims for the 6 month real time storage. The bioburden analysis did not show any bacteria, yeast of fungi growth in the same time period. The transportation simulation also revealed acceptable performance of all kit components after extreme temperature simulation.RNA In Situ Stability:
Objective: Evaluation of the quantity, quality and integrity of whole blood intracellular RNA after storage in the PAXgene tubes. Experiments were performed at various storage temperatures (2 – 8 °C, 18, 22, 25 °C, - 20 °C, - 70 °C) and with freeze/thaw cycles. Sample sizes ranged from 60 to 140 tubes. Yield, purity, CFOS/18S rRNA, and Il1b/18S rRNA were evaluated. The sponsor limited the samples to blood donors with White Blood Cell (WBC) counts between 4.8 – 11.0 x 10° cell/ml of blood.
Results: The RNA yield, purity, integrity based on the sponsors developed Q-RT-PCR assays showed that all samples at all the time points, temperatures and freeze/thaw cycles were within the acceptance range for the individual parameters (one exception). The performance is only evaluated for this range of WBC counts, and is specified in the package insert.d. Detection limit:
Performance evaluation demonstrated that the PAXgene™ Blood RNA system could purify at least 3 µg of RNA with an A260/A280 ratio between 1.8 and 2.2.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
None
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 866.4070 RNA Preanalytical Systems.
(a)
Identification. RNA Preanalytical Systems are devices intended to collect, store, and transport patient specimens, and stabilize intracellular RNA from the specimens, for subsequent isolation and purification of the intracellular RNA for RT-PCR used in in vitro molecular diagnostic testing.(b)
Classification. Class II (special controls). The special control is FDA's guidance document entitled “Class II Special Controls Guidance Document: RNA Preanalytical Systems (RNA Collection, Stabilization and Purification System for RT-PCR Used in Molecular Diagnostic Testing).” See § 866.1(e) for the availability of this guidance document.
0
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY
- A. 510(k) Number: K042613
- B. Purpose for Submission: Clearance of new device
- C. Measurand: Ribonucleic acid (RNA)
D. Type of Test:
Collection, stabilization, and purification of intercellular RNA from whole blood for RT-PCR use in molecular diagnostic testing.
E. Applicant:
PreAnalytiX GmbH
F. Proprietary and Established Names:
PAXgene™ Blood RNA System
G. Regulatory Information:
-
- Regulation section: 21 CFR §866.4070, RNA Preanalytical Systems
-
- Classification: Class II (de novo)
-
- Product code: NTW
-
- Panel: Immunology (82)
H. Intended Use:
-
- Intended use(s):
The PAXgene™ Blood RNA System consists of a blood collection tube (PAXgene™ Blood RNA Tube) and nucleic acid purification kit (PAXgene™ Blood RNA Kit). It is intended for the collection, storage, and transport of blood and stabilization of intracellular RNA in a closed tube and subsequent isolation and purification of host RNA from whole blood for RT-PCR used in molecular diagnostic testing.
- Intended use(s):
Performance characteristics for the PAXgene™ Blood RNA System have only been established with "cfos and IL1B." The user is responsible for establishing appropriate PAXgene™ Blood RNA System performance characteristics for other target transcripts.
1
-
- Indication(s) for use: See intended use above
-
- Special conditions for use statement(s): For professional use only
-
- Special instrument requirements: General laboratory equipment (centrifuges, etc.)
I. Device Description:
The PAXgene™ Blood RNA System consists of:
- the PAXgene™ Blood RNA tubes and .
- the PAXgene™ Blood RNA kit. .
The PAXgene™ Blood RNA tube is of a sterile, plastic, evacuated blood collection tube containing stabilization solution (tetradecyl trimethyl-ammonium oxalate and tartaric acid. These components serve to lyse cells, protect RNA molecules from degradation by ribonucleases (RNases) and prevent induction of gene expression.
The kit consists of 5 aqueous buffer solutions for resuspending, binding, washing, and eluting RNA, RNase-free water, proteinase K, an RNase-Free DNase set, spin columns, microcentrifuge tubes, processing tubes, and secondary blood collection tube closures.
J. Substantial Equivalence Information:
-
- Predicate device name(s): None
-
- Predicate 510(k) number(s): None
-
- Comparison with predicate: Not applicable
K. Standard/Guidance Document Referenced (if applicable);
Not applicable
L. Test Principle:
Blood (2.5 mL) is collected into the PAXgene™ Blood RNA tube by venipuncture. It can be either stored or immediately processed (according to specifications in the labeling). To isolate RNA from the sample, the blood is centrifuged to sediment the nucleic acids and the pellet is resuspended in and washed with RNase-free water. The resulting pellet is dissolved in buffer BR1 and buffer BR2, and proteinase K is added for the enzymatic digestion of proteins. Genomic DNA is sheared by running the sample through a shredder spin column, and ethanol is added to adjust the binding conditions. RNA is selectively bound to the membrane in the PAXgene™ Blood RNA spin column by a short centrifugation. The bound RNA is washed, and residual genomic DNA is removed from the membrane column by treatment of the bound nucleic acid with DNase I. RNA is eluted from the column using the elution buffer
2
provided.
M. Performance Characteristics (if/when applicable):
-
- Analytical performance:
- a. Precision/Reproducibility:
CFOS/18S rRNA and IL1B/18S rRNA Q-RT-PCR Duplex assays.
Objective: The sponsor submitted validation and performance data for two uncleared O-RT-PCR assays for the assessment of performance of the PAXgene Blood RNA System in comparison to a K2EDTA blood collection tube and acid phenol RNA extraction. The assays determine quantitativly the relative level of the c-fos and IL-1ß transcripts compared to 18S rRNA in RNA samples derived from human whole blood. Since CFOS and IL1B offer no diagnostic information, these assays are not intended for diagnostic use. They are ONLY intended for demonstrating that the PAXgene Blood RNA System can be used for RT-PCR.
The validation study uses two types of samples:
K2EDTA (TOTAL: 250 ml blood):
- 5 donors with 5 tubes per donor ●
- 10 ml blood per EDTA tube ●
- RNA was isolated via OIAzol and RNeasy columns, pooled and concentrated via MinElute spin column
- Purified, concentrated RNA was analyzed for yield and purity, aliquoted, and stored at -20 °C.
PAXgene (TOTAL: 960 ml blood):
- 48 donors, 8 tubes per donor (total of 384 PAXgene tubes) ●
- 2.5 ml blood per PAXgene tube
- tubes were incubated at RT for 2 hrs
- RNA was purified, DNase treated, concentrated via MinElute spin ● column and pooled.
- Purified, concentrated RNA was analyzed for yield and purity, aliquoted, and stored at -20 °C.
Experimental design of validation experiments:
The sponsor addressed repeatability and reproducibility and defines these terms within the document as follows:
The repeatability of the assay (within-run precision or intra-assay variability), is the variability of the results from repeated measurements:
- using the same two source samples (n = 10 for each sample) .
- . in the same laboratory (same equipment and same experimenter),
- on the same day, ●
- with the same reagents (identical lots) and ●
3
- . in the same run.
The repeatability of individual runs is expressed as the weighted mean repeatability used for the calculation of overall precision. The weighted mean repeatability is determined and is included in the overall precision calculation.
The reproducibility of the assay, (robustness, run-to-run precision, or inter-assay variability), is the variability of results from repeat measurements
- using the same two source samples .
- in different laboratories (different lots, different equipment and . different experimenters)
- . on different days
- . and in different runs.
Therefore, reproducibility investigations involve repeats of the complete experiment in different laboratories. To establish the suitability of the precision for day-to-day work, different lots of reagents are investigated as additional parameters that may have a negative impact on precision. The reproducibility between laboratories is determined, but also not specified in detail, because it is included in the overall precision calculation and therefore will be assessed as its part.
| Combi-
nation1) | Reagent
Combination
Run No. (k) | Run2) | RNA
sample3) | Replicates
per RNA
sample | Number of
ΔCTvalues per RNA
sample | Number of
ΔΔCT values per run |
|--------------------|---------------------------------------|-------|-----------------|---------------------------------|------------------------------------------|----------------------------------|
| A | 1 | A1 | K | 10 | 10 | 10 |
| | | | T | 10 | 10 | 10 |
| | 2 | A2 | K | 10 | 10 | 10 |
| | | | T | 10 | 10 | 10 |
| | 3 | A3 | K | 10 | 10 | 10 |
| | | | T | 10 | 10 | 10 |
| B | 4 | B1 | K | 10 | 10 | 10 |
| | | | T | 10 | 10 | 10 |
| | 5 | B2 | K | 10 | 10 | 10 |
| | | | T | 10 | 10 | 10 |
| | 6 | B3 | K | 10 | 10 | 10 |
| | | | T | 10 | 10 | 10 |
| C | 7 | C1 | K | 10 | 10 | 10 |
| | | | T | 10 | 10 | 10 |
| | 8 | C2 | K | 10 | 10 | 10 |
| | | | T | 10 | 10 | 10 |
| | 9 | C3 | K | 10 | 10 | 10 |
| | | | T | 10 | 10 | 10 |
| Total | | | | | 180 | 90 |
Table 6: Summary of measurement runs for the determination of overall precision
Combination of experimenter, laboratory (equipment), day, TagMan plate
21 Measurement series (run), Established by reagent lots within the combination (A. B. C)
determined by reagent lots 3 K = calibrator RNA, T = test RNA
4
Note: Under 1, technician-to-technician, lab-to-lab, and day-to-day variability has been combined in this study.
Results: The sponsor performed an appropriate validation of their submitted assay by using 3 different component lots, in the hands of 3 different experimenters, in 3 different laboratories (equipment), on 3 different days. The sponsor provided all raw CT data and demonstrated the performance of their assays within the expected limits.
Precision/Reproducibility of the PAXgene Blood RNA System.
Objective: Determination of the repeatability, reproducibility and reliability of the PAXgene Blood RNA System.
Two experiments were performed: Experiment 1:
- 14 donors (WBC counts within 4.8 to 11.0 x 10° cells/ml blood) ●
- 12 tubes per donor (total 168 PAXgene tubes)
- PAXgene Blood RNA system Lot No. VL1 (ONLY one lot!)
- 3 technicians. Each technician processed 4 tubes per subject (total of 56 ● tubes per technician) in 3 runs (Run #1: donor 1-3 (12 tubes); Run #2: donor 4-9 (24 tubes); Run #3: donor 10-14 (20 tubes)
RNA vield (absorbance at 260 nm) and purity (260nm/280nm absorbance ratio) were determined for each sample.
Repeatibility was determined by evaluating the vield and purity of four samples from one donor processed by one technician.
Reproducibility was determined by evaluating the yield and purity of 12 samples from one donor processed by three technicians. The repeatability and reproducibility was determined separately for each donor because of the differences between individuals.
Experiment 2:
- 30 donors (WBC counts within 4.8 to 11.0 x 10° cells/ml blood) ●
- 12 tubes per donor (total 360 PAXgene tubes) ●
- Blood from filled PAXgene tubes from 3 donors were pooled and realiquoted into empty tubes, generating 10 donor pools with 36 tubes each.
- PAXgene Blood RNA system Lot No. VL1, VL2, VL3
- 3 technicians. Each technician processed 4 tubes per donor pool per ● day. This was repeated with 2 additional kit lots.
RNA yield (absorbance at 260 nm) and purity (260nm/280nm absorbance ratio) were determined for each sample. For this experiment the RNA purity was also evaluated by electropherograms generated by BioAnalyzer. The isolated total RNA was further tested for degradation with the CFOS and IL1B Q-RT-PCR assay.
5
Results: the sponsor was able to show that the RNA vield and the RNA purity and quality were within the specification ranges. The min/max % CV repeatability for the quadruplicate preparation per donor pool within each lot and user were 3.4 and 28.8, respectively, with an overall % CV of 11.9. The min/max % CVs reproducibility within each user and between all lots were 8.7 and 20.1, respectively, with an overall % CV of 14.9. The min/max % CV reproducibility within all lots and between all users were 8.7 and 23.1, respectively, with an overall % CV of 16.4. The electropherograms demonstrated that the device repeatedly generates high quality total cellular RNA from whole blood. The Q-RT-PCR assay demonstrated that the transcripts CFOS and IL1B can be repeatedly measured within the assays limits utilizing different device lots, at different days, with different users in different laboratories.
RNA Purity, DNA Contamination, RNA Yield.
Objective:
Determination of the purity of RNA in samples, the genomic DNA (gDNA) in RNA samples and the nucleic acid yield from human whole blood specimens taken from normal subject population resulting from collection and processing of human whole blood in the PAXgene RNA Blood System.
Experimental design:
- . 10 donors
- 2 tubes per donor (total 20 PAXgene tubes) + 1 EDTA tube per . donor for WBC count (10 EDTA tubes)
- storage for 24 hrs at 18-22 ℃, tubes were processed, RNA isolated ●
- . RNA vield and purity were determined via absorbance measurement at 260 and 280 nm
- . Percent gDNA in total nucleic acid preparation was determined using beta-actin PCR
Results: All samples for all parameter fulfilled the acceptance criteria.
RT-PCR Inhibition.
Objective:
Determination of RT-PCR inhibition introduced into RNA isolates by components of the PAXgene Blood RNA Kit
Experimental Design:
- 22 blank eluates form columns
- template RNA for RT-PCR assay was isolated from confluent layer of HeLa cells
6
- Test samples were formulated each containing 40 ng of HeLa RNA template plus 0, 10, 20, 30, 40% volume of volume of blank eluate
- Template RNA with eluate was tested in duplicate in a one-step ACTB RT-PCR assay
Results: All samples demonstrated that the kit components do not introduce any inhibition for an RT-PCR assay.
-
b. Linearity/assay reportable range:
The linearity and range was determined within 0.2 to 7.8 ng for CFOS and 0.1 to 7.8 ng for IL1B total input nucleic acid per reaction. The total input mass of nucleic acid per reaction can contain up to 25% DNA for CFOS and up to 5% DNA for IL1B without affecting the performance characteristics of the assay. -
Traceability, Stability, Expected values (controls, calibrators, or methods): C. Stability of PAXgene Tubes:
Objective: Determine the shelf life of the PAXgene Blood RNA Tube. Determination of physical attributes of the tubes: -
draw volume
-
liquid additive volume
-
closure performance .
Chemical attributes of the liquid reagent:
- . pH
- conductivity ●
- density
- . chemical component concentration
Analysis of tube function:
- RNA yield (A260 nm, 95% ≥3 µg/tube) ●
- Purity (ratio of A260 and A280, between 1.8 2.2) .
- Relative levels of CFOS and IL1B (CFOS/18S rRNA and IL1B/18S rRNA . duplex Q-RT-PCR assay, CFOS within 2.34 CT and IL1B within 1.94 CT).
Blood was collected in PAXgene tubes that had been stored at designated test time points (TTP's). RNA stabilizing properties of the tubes were investigated by preparing purified RNA from blood-filled tubes stored at 18-25°C for 0, 1 and 3 days with the PAXgene blood RNA kit (10 donors x 3 times of storage of blood filled tubes x 2 preparations). All PAXgene Blood RNA kits used in these studies were stored prior to use at 2-8°C to minimize kit aging. IMPORTANT: All claims of stability that are based on data from accelerated stability studies will be confirmed in parallel in real time stability studies. Table 1 shows the number of tubes tested in functional tests at each TTP.
7
| Stability Conditions | TTPs at this
temperature | number of tubes for
thistemperature study | total |
|--------------------------|-----------------------------------------------|----------------------------------------------|-------|
| 40°C study (accelerated) | 19w, 28w | 2 TTP x 60tubes/TTP | 120 |
| 50°C study (accelerated) | 10w, 15w | 2 TTP x 60 tubes/TTP | 120 |
| 25°C study (real time) | 0, 6m, 9m, 12m,
13m, 15m, 16m,
18m, 19m | 9 TTP x 60 tubes/TTP | 810 |
Table 1: Functional Test TTPs and number of tubes scheduled for testing
Results: Accelerated stability studies have been completed at the time of this report. Real time stability studies are ongoing, and only results of 6 months storage at 25°C are presented. The sponsor interprets that the data support a shelf live of 19 months storage at 25 °C.
The physical attributes were evaluated for 3 different lots of tubes. The draw volume, liquid additive volume, and closure performance meet the acceptance criteria. For the chemical attributes as well as the functional performance it is not clear whether 1 or 3 lots of tubes were used. For the presented data the pH. conductivity, and density as well as the RNA yield, purity and CFOS and IL1B transcript stability were in the expected ranges for the 6 months real time storage.
Stability of PAXgene Blood RNA Kit component:
Objective: Determine the shelf life of the PAXgene Blood RNA Kit component. Evaluation of different storage conditions via:
- Real time and accelerated stability study
- Open bottle study
- . Simulated transportation study (simulated extreme temperatures, -20°C-40°C)
Determination of functional stability done with purified HeLa cell RNA as starting material. Two reagent sets were used per tested time point (4 blank eluates (RNase-free water as starting material), and 8 RNA eluates. The following parameters were addressed:
- Determination of recovery of input RNA (HeLa cell RNA) ●
- Determination of variability of recovery of input RNA ●
- . Determination of the degree of inhibition of an RT-PCR assay (via ACTB RT-PCR monoplex assay.
Evaluation of physical and chemical parameters:
- pH
- conductivity ●
- . density
Bioburden Analysis:
● Test of buffers for total bacterial and yeast counts per ml
Results: The RNA recovery, CV of recovery, degree on inhibition, pH, conductivity, and density (for all buffers) were in the expected ranges for the 6 months real time storage. Furthermore, the Proteinase K and the DNase I activity performed to the sponsors claims for the 6 month real time storage.
8
The bioburden analysis did not show any bacteria, yeast of fungi growth in the same time period. The transportation simulation also revealed acceptable performance of all kit components after extreme temperature simulation.
RNA In Situ Stability:
To determine the stability of RNA in samples stored at different temperatures and times, the sponsor performed several RNA In Situ stability experiments that are summarize in Table 2.
Objective: Evaluation of the quantity, quality and integrity of whole blood intracellular RNA after storage in the PAXgene tubes.
| Storage Temperature | 2 – 8 °C | 18, 22, 25 °C | - 20 °C | - 70 °C | Freeze/Thaw |
|---|---|---|---|---|---|
| # of donors | 10 | 10 | 10 | 10 | 10 |
| Eligibility | 1.8 to | 1.9 to | 1.10 to | 1.11 to | 1.12 to |
| WBC per ml | 11.0 x 106 cells | 11.0 x 106 cell | 11.0 x 106 cell | 11.0 x 106 cell | 11.0 x 106 cells |
| PAXgene tubes/donor | 12 | 14 | 14 | 10 | 6 |
| Total # of tubes | 120 | 140 | 140 | 100 | 60 |
| Used in experiment | |||||
| Storage before start | |||||
| of experiment | 2 hrs RT | 2 hrs RT | 2 hrs RT | 2 hrs RT | 24 hrs RT |
| Time points | |||||
| (# of tubes) | t0 (2 tubes) | ||||
| t1D (2 tubes) | |||||
| t2D (2 tubes) | |||||
| t3D (2 tubes) | |||||
| t4D (2 tubes) | |||||
| t5D (2 tubes) | t0 (2 tubes) | ||||
| t1D (2 tubes) | |||||
| t3D (2 tubes) | t0 (2 tubes) | ||||
| t1m (2 tubes) | |||||
| t2m (2 tubes) | |||||
| t3m (2 tubes) | |||||
| t4m (2 tubes) | |||||
| t5m (2 tubes) | |||||
| t6m (2 tubes) | t0 (2 tubes) | ||||
| t3m (2 tubes) | |||||
| t6m (2 tubes)) | t0 (2 tubes) | ||||
| 1st freeze/thaw | |||||
| (2 tubes) | |||||
| 2nd freeze/thaw | |||||
| (2 tubes) | |||||
| Yield (> 3 µg/tube) | 260 nm | 260 nm | 260 nm | 260 nm | 260 nm |
| Purity (ratio 1.8-2.2) | 260nm/280nm | 260nm/280nm | 260nm/280nm | 260nm/280nm | 260nm/280nm |
| CFOS/18S rRNA | X | X | X | X | NA |
| Il1b/18S rRNA | X | X | X | X | X |
Table 2: Experimental Design of RNA In Situ Stability at different conditions
The RNA yield, purity, integrity based on the sponsors developed Q-RT-PCR assays showed that all samples at all the time points, temperatures and freeze/thaw cycles were within the acceptance range for the individual parameters (one exception). The sponsor limited the samples to blood donors with White Blood Cell (WBC) counts between 4.8 – 11.0 x 10° cell/ml of blood. The performance is only evaluated for this range of WBC counts, and is specified in the package insert.
d. Detection limit:
Performance evaluation demonstrated that the PAXgene™ Blood RNA system could purify at least 3 µg of RNA with an A260/A280 ratio between 1.8 and 2.2.
9
- e. Analytical specificity: See above
- Assay cut-off: f. Not applicable.
-
- Comparison studies:
- a. Method comparison with predicate device: Not applicable.
- b. Matrix comparison: Not applicable.
-
- Clinical studies:
- a. Clinical Sensitivity: Not applicable.
- b. Clinical specificity: Not applicable.
- c. Other clinical supportive data (when a. and b. are not applicable): Not applicable.
-
- Clinical cut-off: Not applicable
-
- Expected values/Reference range: Not applicable
N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.
O. Conclusion:
The petition for Evaluation of Automatic Class III Designation for this device is accepted. The device is classified as Class II under regulation 21 CFR 866.4060 with special controls. The special control guidance document "RNA Preanalytical Systems (RNA Collection, Stabilization and Purification Systems for RT-PCR used in Molecular Diagnostic Testing)" will be available shortly.